| Autor: |
Coffin JD; The University of Montana, Missoula, Montana., Homer-Bouthiette C; University of South Carolina School of Medicine, Columbia, South Carolina., Hurley MM; Department of Medicine, University of Connecticut School of Medicine, UCONN Health, Farmington, Connecticut. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of the Endocrine Society [J Endocr Soc] 2018 May 28; Vol. 2 (7), pp. 657-671. Date of Electronic Publication: 2018 May 28 (Print Publication: 2018). |
| DOI: |
10.1210/js.2018-00105 |
| Abstrakt: |
The fibroblast growth factor (FGF) regulatory axis is phylogenetically ancient, evolving into a large mammalian/human gene family of 22 ligands that bind to four receptor tyrosine kinases for a complex physiologic system controlling cell growth, differentiation, and metabolism. The tissue targets for the primary FGF function are mainly in cartilage and in bone for morphogenesis, mineralization, and metabolism. A multitude of complexities in the FGF ligand-receptor signaling pathways have made translation into therapies for FGF-related bone disorders such as osteomalacia, osteoarthritis, and osteoporosis difficult but not impossible. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
